Literature DB >> 23746196

Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.

Chunyong Ding1, Yusong Zhang, Haijun Chen, Zhengduo Yang, Christopher Wild, Lili Chu, Huiling Liu, Qiang Shen, Jia Zhou.   

Abstract

Oridonin (1), a complex ent-kaurane diterpenoid isolated from the traditional Chinese herb Isodon rubescens , has demonstrated great potential in the treatment of various human cancers due to its unique and safe anticancer pharmacological profile. Nevertheless, the clinical development of oridonin for cancer therapy has been hampered by its relatively moderate potency, limited aqueous solubility, and poor bioavailability. Herein, we report the concise synthesis of a series of novel nitrogen-enriched oridonin derivatives with thiazole-fused A-ring through an efficient protecting group-free synthetic strategy. Most of them, including compounds 7-11, 13, and 14, exhibited potent antiproliferative effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicromolar IC50 values as well as markedly enhanced aqueous solubility. These new analogues obtained by rationally modifying the natural product have been demonstrated not only to significantly induce the apoptosis and suppress growth of triple-negative MDA-MB-231 breast cancer both in vitro and in vivo but also effective against drug-resistant ER-positive MCF-7 clones.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746196      PMCID: PMC3712786          DOI: 10.1021/jm400367n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

Review 1.  Drug-like properties and the causes of poor solubility and poor permeability.

Authors:  C A Lipinski
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

2.  2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.

Authors:  Ao Zhang; Wennan Xiong; James E Hilbert; Emily K DeVita; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

3.  Medicine from plants.

Authors:  P H Abelson
Journal:  Science       Date:  1990-02-02       Impact factor: 47.728

4.  The antitumor and antibacterial activity of the Isodon diterpenoids.

Authors:  E Fujita; Y Nagao; K Kaneko; S Nakazawa; H Kuroda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1976-09       Impact factor: 1.645

5.  Antitumor activity of diterpenoids, trichorabdals A, B, and C, and the related compounds: synergism of two active sites.

Authors:  M Node; M Sai; K Fuji; E Fujita; S Takeda; N Unemi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-04       Impact factor: 1.645

6.  Antitumor activity of acylated oridonin.

Authors:  E Fujita; Y Nagao; T Kohno; M Matsuda; M Ozaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1981-11       Impact factor: 1.645

7.  Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation.

Authors:  Chun-Ling Zhang; Li-Jun Wu; Hai-Jun Zuo; Shin-ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  J Pharmacol Sci       Date:  2004-10-09       Impact factor: 3.337

8.  Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929.

Authors:  Chun-Ling Zhang; Li-Jun Wu; Shin-ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  Biol Pharm Bull       Date:  2004-10       Impact factor: 2.233

9.  Instability of succinyl ester linkages in O2'-monosuccinyl cyclic AMP-protein conjugates at neutral pH.

Authors:  M C Carter; M E Meyerhoff
Journal:  J Immunol Methods       Date:  1985-08-02       Impact factor: 2.303

10.  Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.

Authors:  Dahong Li; Lei Wang; Hao Cai; Yihua Zhang; Jinyi Xu
Journal:  Molecules       Date:  2012-06-18       Impact factor: 4.411

View more
  32 in total

1.  Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.

Authors:  Richard A Graves; Grace A Ledet; Elena Y Glotser; Demaurian M Mitchner; Levon A Bostanian; Tarun K Mandal
Journal:  Eur J Pharm Sci       Date:  2015-04-28       Impact factor: 4.384

2.  Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.

Authors:  Na Ye; Yingmin Zhu; Haijun Chen; Zhiqing Liu; Fang C Mei; Christopher Wild; Haiying Chen; Xiaodong Cheng; Jia Zhou
Journal:  J Med Chem       Date:  2015-07-16       Impact factor: 7.446

3.  Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Na Ye; Corbin D Ester; Ailian Xiong; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-10-31       Impact factor: 7.446

4.  Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.

Authors:  Shengtao Xu; Lingling Pei; Chengqian Wang; Yun-Kai Zhang; Dahong Li; Hequan Yao; Xiaoming Wu; Zhe-Sheng Chen; Yijun Sun; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2014-05-28       Impact factor: 4.345

5.  Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Christopher Wild; Tianzhi Wang; Mark A White; Qiang Shen; Jia Zhou
Journal:  Org Lett       Date:  2013-07-08       Impact factor: 6.005

6.  Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads.

Authors:  Ye Ding; Dengfeng Li; Chunyong Ding; Pingyuan Wang; Zhiqing Liu; Eric A Wold; Na Ye; Haiying Chen; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

7.  Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.

Authors:  Zhiqing Liu; Haiying Chen; Pingyuan Wang; Yi Li; Eric A Wold; Paul G Leonard; Sarah Joseph; Allan R Brasier; Bing Tian; Jia Zhou
Journal:  J Med Chem       Date:  2020-04-22       Impact factor: 7.446

Review 8.  Discovery and development of natural product oridonin-inspired anticancer agents.

Authors:  Ye Ding; Chunyong Ding; Na Ye; Zhiqing Liu; Eric A Wold; Haiying Chen; Christopher Wild; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

9.  Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis.

Authors:  Fredrick J Bohanon; Xiaofu Wang; Chunyong Ding; Ye Ding; Geetha L Radhakrishnan; Cristiana Rastellini; Jia Zhou; Ravi S Radhakrishnan
Journal:  J Surg Res       Date:  2014-03-20       Impact factor: 2.192

10.  Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis.

Authors:  Fredrick J Bohanon; Xiaofu Wang; Brittany M Graham; Chunyong Ding; Ye Ding; Geetha L Radhakrishnan; Cristiana Rastellini; Jia Zhou; Ravi S Radhakrishnan
Journal:  J Surg Res       Date:  2015-08-05       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.